Saphris gains indications

Merck announced that Saphris (asenapine sublingual tablets) has been approved for two additional indications: 1) the maintenance treatment of schizophrenia and 2) as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Saphris is already indicated for acute treatment of schizophrenia in adults and as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder.

For more information call (800) 672-6372 or visit www.saphris.com.